CHD1L

Across TCGA pan-cancer cohorts, CHD1L mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CHD1L data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CHD1L mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CHD1L expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where CHD1L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.939	0.704	.003	11	view →
HNSC	OS	Median	III,IV	0.792	0.934	.013	7	view →
PDAC	DFS	Tertile	II,III,IV	0.454	0.250	.027	4	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	3	view →
UCEC	DFS	Median	All	1.000	0.937	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CHD1L–CCRCC (DFS)

Open the CCRCC breakdown →